NCT00322985 - A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2014

Study Completion Date

July 31, 2014

Conditions

T-cell Lymphoma

Interventions

DRUG

Lenalidomide

25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.

Trial Locations (5)

Tom Baker Cancer Centre, Calgary

Cancer Care Manitoba, Winnipeg

Queen Elizabeth II, Health Services Centre, Halifax

Ottawa Hospital General Campus, Ottawa

Cross Cancer Institute, Edmonton